BRIEF-Dizal Completes Enrollment For Its Phase II Pivotal Study of Sunvozertinib vs Platinum Doublet

Reuters06-19

June 19 (Reuters) - Dizal Pharmaceutical Co Ltd 688192.SS:

DIZAL COMPLETES ENROLLMENT FOR ITS PHASE III PIVOTAL STUDY OF SUNVOZERTINIB VERSUS. PLATINUM DOUBLET IN TREATMENT NAÏVE NSCLC PATIENTS WITH EGFR EXON20 INSERTIONAL MUTATIONS

Source text: ID:nPn8mZfgqa

Further company coverage: 688192.SS

((reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2544619861?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 23:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544619861","market":"nz","top_or_hot":-1,"title":"BRIEF-Dizal Completes Enrollment For Its Phase II Pivotal Study of Sunvozertinib vs Platinum Doublet","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Dizal Completes Enrollment For Its Phase II Pivotal Study of Sunvozertinib vs Platinum Doublet</title></head><body><p><span>June 19 (Reuters)</span><span> - </span>Dizal Pharmaceutical Co Ltd <span>688192.SS</span>:</p><ul><li><p>DIZAL COMPLETES ENROLLMENT FOR ITS PHASE III PIVOTAL STUDY OF SUNVOZERTINIB VERSUS. PLATINUM DOUBLET IN TREATMENT NAÏVE NSCLC PATIENTS WITH EGFR EXON20 INSERTIONAL MUTATIONS</p></li></ul><p>Source text: <span>ID:nPn8mZfgqa</span></p><p>Further company coverage: <span>688192.SS</span></p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Dizal Completes Enrollment For Its Phase II Pivotal Study of Sunvozertinib vs Platinum Doublet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Dizal Completes Enrollment For Its Phase II Pivotal Study of Sunvozertinib vs Platinum Doublet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-19 23:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Dizal Completes Enrollment For Its Phase II Pivotal Study of Sunvozertinib vs Platinum Doublet</title></head><body><p><span>June 19 (Reuters)</span><span> - </span>Dizal Pharmaceutical Co Ltd <span>688192.SS</span>:</p><ul><li><p>DIZAL COMPLETES ENROLLMENT FOR ITS PHASE III PIVOTAL STUDY OF SUNVOZERTINIB VERSUS. PLATINUM DOUBLET IN TREATMENT NAÏVE NSCLC PATIENTS WITH EGFR EXON20 INSERTIONAL MUTATIONS</p></li></ul><p>Source text: <span>ID:nPn8mZfgqa</span></p><p>Further company coverage: <span>688192.SS</span></p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nTUA7WSLJL:1","article_id":"2544619861","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544619861","pubTimestamp":1750348535,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Dizal Completes Enrollment For Its Phase II Pivotal Study of Sunvozertinib vs Platinum DoubletJune 19 (Reuters) - Dizal Pharmaceutical Co Ltd 688192.SS:DIZAL COMPLETES ENROLLMENT FOR ITS PHASE I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688192":"迪哲医药","BK0239":"医药制造"},"translate_title":"BRIEF-Dizal完成Sunvozertinib与铂类双联药物的II期关键研究的入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688192":0.9},"content_text":"BRIEF-Dizal Completes Enrollment For Its Phase II Pivotal Study of Sunvozertinib vs Platinum DoubletJune 19 (Reuters) - Dizal Pharmaceutical Co Ltd 688192.SS:DIZAL COMPLETES ENROLLMENT FOR ITS PHASE III PIVOTAL STUDY OF SUNVOZERTINIB VERSUS. PLATINUM DOUBLET IN TREATMENT NAÏVE NSCLC PATIENTS WITH EGFR EXON20 INSERTIONAL MUTATIONSSource text: ID:nPn8mZfgqaFurther company coverage: 688192.SS ((reuters.briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2544619861","isCrawlerRequest":true}